At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 28 enrolled
Drug / intervention
Amla +1 moredrug
Likely dose
Amla 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Amla Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion.
In Brief
A Phase 3 clinical trial evaluating Amla and Placebo for Metabolic Syndrome. Completed, enrolled 28 participants across 1 site.
Detailed Summary
Amla has demonstrated promising effects in the treatment of obesity, dyslipidemia, hypertension, insulin secretion, among others. The above mentioned findings show that Amla has an excellent potential for the prevention and treatment of metabolic syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesMexico
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartApr 2019
Primary CompletionOct 2021
Study CompletionMar 2022
TodayJul 2026
First PostedAug 16, 2018
Enrollment StartApr 1, 2019
Primary CompletionOct 30, 2021
Study CompletionMar 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.9 years ago
Interventions
Amladrug
Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
Placebodrug
Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days